174 related articles for article (PubMed ID: 11355931)
1. Developmental approaches in immunological control of acute myelogenous leukaemia.
Torelli GF; Orsini E; Guarini A; Kell J; Foà R
Best Pract Res Clin Haematol; 2001 Mar; 14(1):189-209. PubMed ID: 11355931
[TBL] [Abstract][Full Text] [Related]
2. Acute myeloid leukemia and novel biological treatments: monoclonal antibodies and cell-based gene-modified immune effectors.
Tettamanti S; Magnani CF; Biondi A; Biagi E
Immunol Lett; 2013; 155(1-2):43-6. PubMed ID: 24076117
[TBL] [Abstract][Full Text] [Related]
3. Cancer immunotherapy.
Baxevanis CN; Perez SA; Papamichail M
Crit Rev Clin Lab Sci; 2009; 46(4):167-89. PubMed ID: 19650714
[TBL] [Abstract][Full Text] [Related]
4. Active vaccination after allogeneic bone marrow cell transplantation: a new option in the immunotherapy of cancer?
Zöller M; Matzku S
Arch Immunol Ther Exp (Warsz); 2002; 50(3):197-224. PubMed ID: 12098935
[TBL] [Abstract][Full Text] [Related]
5. Cancer vaccines for patients with acute myeloid leukemia--definition of leukemia-associated antigens and current clinical protocols targeting these antigens.
Greiner J; Döhner H; Schmitt M
Haematologica; 2006 Dec; 91(12):1653-61. PubMed ID: 17145602
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapeutic strategies for relapse control in acute myeloid leukemia.
Martner A; Thorén FB; Aurelius J; Hellstrand K
Blood Rev; 2013 Sep; 27(5):209-16. PubMed ID: 23871358
[TBL] [Abstract][Full Text] [Related]
7. Immunological weapons against acute myeloid leukaemia.
Galea-Lauri J
Immunology; 2002 Sep; 107(1):20-7. PubMed ID: 12225359
[TBL] [Abstract][Full Text] [Related]
8. Current strategies in immunotherapy for acute myeloid leukemia.
Lichtenegger FS; Schnorfeil FM; Hiddemann W; Subklewe M
Immunotherapy; 2013 Jan; 5(1):63-78. PubMed ID: 23256799
[TBL] [Abstract][Full Text] [Related]
9. Treatment of minimal residual disease in acute myelogenous leukemia (AML): focus on immunotherapeutic options.
Simonsson B
Leukemia; 1996 Jun; 10 Suppl 2():s44-5. PubMed ID: 8649052
[No Abstract] [Full Text] [Related]
10. Immunotherapy for acute myeloid leukemia (AML): a potent alternative therapy.
Acheampong DO; Adokoh CK; Asante DB; Asiamah EA; Barnie PA; Bonsu DOM; Kyei F
Biomed Pharmacother; 2018 Jan; 97():225-232. PubMed ID: 29091870
[TBL] [Abstract][Full Text] [Related]
11. Peptide vaccines for patients with acute myeloid leukemia.
Schmitt M; Casalegno-Garduño R; Xu X; Schmitt A
Expert Rev Vaccines; 2009 Oct; 8(10):1415-25. PubMed ID: 19803762
[TBL] [Abstract][Full Text] [Related]
12. New strategies in the treatment of acute myelogenous leukemia (AML): in vitro culture of aml cells--the present use in experimental studies and the possible importance for future therapeutic approaches.
Bruserud O; Gjertsen BT; Foss B; Huang TS
Stem Cells; 2001; 19(1):1-11. PubMed ID: 11209086
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
Liu Y; Bewersdorf JP; Stahl M; Zeidan AM
Blood Rev; 2019 Mar; 34():67-83. PubMed ID: 30553527
[TBL] [Abstract][Full Text] [Related]
14. Acute myeloid leukaemia and the immune system: implications for immunotherapy.
Barrett AJ
Br J Haematol; 2020 Jan; 188(1):147-158. PubMed ID: 31782805
[TBL] [Abstract][Full Text] [Related]
15. Biologic and immunologic therapy of ovarian cancer.
Bookman MA; Berek JS
Hematol Oncol Clin North Am; 1992 Aug; 6(4):941-65. PubMed ID: 1500395
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy prospects for acute myeloid leukaemia.
Barrett AJ; Le Blanc K
Clin Exp Immunol; 2010 Aug; 161(2):223-32. PubMed ID: 20529084
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of acute myeloid leukemia: current approaches.
Smits EL; Berneman ZN; Van Tendeloo VF
Oncologist; 2009 Mar; 14(3):240-52. PubMed ID: 19289488
[TBL] [Abstract][Full Text] [Related]
18. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
19. Cancer immunotherapy.
Schuster M; Nechansky A; Kircheis R
Biotechnol J; 2006 Feb; 1(2):138-47. PubMed ID: 16892244
[TBL] [Abstract][Full Text] [Related]
20. Engineering dendritic cell grafts for clinical trials in cellular immunotherapy of cancer: example of chronic myelogenous leukemia.
Dietz AB; Litzow MR; Gastineau DA; Vuk-Pavlović S
Croat Med J; 2001 Aug; 42(4):428-35. PubMed ID: 11471194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
